Stocks & Investing
Stocks and Investing
Stocks and Investing
Tue, June 25, 2024
[ Tue, Jun 25th 2024
] - WOPRAI
[ Tue, Jun 25th 2024
] - WOPRAI
[ Tue, Jun 25th 2024
] - WOPRAI
[ Tue, Jun 25th 2024
] - WOPRAI
[ Tue, Jun 25th 2024
] - WOPRAI
[ Tue, Jun 25th 2024
] - WOPRAI
[ Tue, Jun 25th 2024
] - WOPRAI
[ Tue, Jun 25th 2024
] - WOPRAI
[ Tue, Jun 25th 2024
] - WOPRAI
[ Tue, Jun 25th 2024
] - WOPRAI
[ Tue, Jun 25th 2024
] - WOPRAI
[ Tue, Jun 25th 2024
] - WOPRAI
[ Tue, Jun 25th 2024
] - WOPRAI
[ Tue, Jun 25th 2024
] - WOPRAI
[ Tue, Jun 25th 2024
] - WOPRAI
[ Tue, Jun 25th 2024
] - WOPRAI
[ Tue, Jun 25th 2024
] - WOPRAI
[ Tue, Jun 25th 2024
] - WOPRAI
[ Tue, Jun 25th 2024
] - WOPRAI
[ Tue, Jun 25th 2024
] - WOPRAI
[ Tue, Jun 25th 2024
] - WOPRAI
[ Tue, Jun 25th 2024
] - WOPRAI
[ Tue, Jun 25th 2024
] - WOPRAI
Mon, June 24, 2024
[ Mon, Jun 24th 2024
] - WOPRAI
[ Mon, Jun 24th 2024
] - WOPRAI
[ Mon, Jun 24th 2024
] - WOPRAI
[ Mon, Jun 24th 2024
] - WOPRAI
Joseph Pantginis Reiterated (APRE) at Strong Buy and Held Target at $20 on, Jun 24th, 2024
Joseph Pantginis of HC Wainwright & Co., Reiterated "Aprea Therapeutics, Inc." (APRE) at Strong Buy and Held Target at $20 on, Jun 24th, 2024.
Joseph has made no other calls on APRE in the last 4 months.
There is 1 other peer that has a rating on APRE. Out of the 1 peers that are also analyzing APRE, 0 agree with Joseph's Rating of Hold.
This is the rating of the analyst that currently disagrees with Joseph
- Robert Driscoll of "Wedbush" Maintained at Buy with Increased Target to $11 on, Wednesday, March 27th, 2024
